Activated protein C versus protein C in severe sepsis

Critical Care Medicine

Volumn 29, Issue 7 SUPPL., 2001, Pages

  Yan, S B ^a   Dhainaut, J F ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Activated protein C; Coagulation; Endothelial protein C receptor; Protein C; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; PLACEBO; PROTEIN C;

CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM LESION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS;

EID: 0034917322     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200107001-00024     Document Type: Conference Paper

References (75)

1. Activated protein C differs from protein C pharmacokinetically and pharmacodynamically
2. Antithrombotic and anti-inflammatory agents of the protein C anticoagulant pathway
3. The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway
4. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
5. Correlates of antithrombin, protein G protein S and TFPI in a healthy elderly cohort
6. Protein C activity in healthy volunteers: Influence of age, sex, smoking and oral contraceptives
7. Absence of thrombosis in subjects with heterozygous protein C deficiency
8. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases
9. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
10. Aging-associated changes in indices of thrombin generation and protein C activation in humans: Normative aging study
11. Direct detection of activated protein C in blood from human subjects
12. Quantification of circulating activated protein C in human plasma by immunoassays: Enzyme levels are proportional to total protein C levels
13. A sensitive and facile assay for the measurement of activated protein C activity levels in vivo
14. Contribution of plasma proteinase inhibitors to the regulation of activated protein C in plasma
15. Inhibition and complexation of activated protein C by two major inhibitors in plasma
16. Activation of protein C and its distribution between its inhibitors, protein C inhibitor, α1-antitrypsin and α2-macroglobulin, in patients with disseminated intravascular coagulation
17. Generation of activated protein C during thrombolysis
18. Development of the hemostatic system in the neonate and young infant
19. Prothrombin and protein C in early childhood: Normal adult levels are not achieved until the fourth year of life
20. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency
21. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects
22. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with purified protein C concentrate
23. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface
24. The endothelial cell protein C receptor
25. The endothelial cell protein C receptor (EPCR) functions as a primary receptor for protein C activation on endothelial cells in arteries, veins and capillaries
26. Molecular events that control the protein C anticoagulant pathway
27. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates
28. Circulating activated protein C in subjects with heterozygous Gln506-Factor V
29. Brain-specific protein C activation during carotid artery occlusion in humans
30. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes
31. Activated protein C correlates inversely with thrombin levels in resting healthy individuals
32. Association of plasma levels of activated protein C with recanalization of the infarct-related coronary artery after thrombolytic therapy in acute myocardial infarction
33. Paradoxic elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysis
34. Inflammation and thrombosis: Mutual regulation by protein C
35. Cytokines and anticytokines in the pathogenesis of sepsis
36. Neutrophil and endothelial cell interactions in sepsis
37. Prognostic value of protein C levels in neutropenic patients at high risk of severe septic complications
38. Safety and dose-relationship of recombinant human activated protein C (rhAPC) on coagulopathy in severe sepsis
39. Efficacy and safety of recombinant human activated protein C for treatment of patients with severe sepsis
40. Low levels of protein C are associated with poor outcome in severe sepsis
41. Time course of hemostatic abnormalities in sepsis and its relation to outcome
42. Protein C in the treatment of coagulopathy in meningococcal sepsis
43. Protein C administration in meningococcal septicaemia
44. Meningococcal septicaemia: Treatment with protein C concentrate
45. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans
46. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate
47. Protein C concentrate for meningococcal purpura fulminans
48. Protein C concentrate and recombinant tissue plasminogen activator in meningococcal septic shock
49. Protein C in the treatment of coagulopathy in meningococcal disease
50. Protein C in the treatment of coagulopathy in meningococcal disease
51. Protein C substitution in sepsis-associated purpura fulminans
52. Treatment of purpura fulminans in meningococcemia with protein C concentrate
53. Use of protein C concentrate, heparin and haemodiafiltration in meningococcus-induced purpura fulminans
54. The use of protein C in severe meningococcal sepsis
55. Description of compensated and uncompensated disseminated intravascular coagulation (DIC) responses (non-overt and overt DIC) in baboon models of intravenous and intraperitoneal Escherichia coli sepsis and in the human model of endotexemia: Toward a better definition of DIC
56. Endotoxin enhances tissue factor and supresses thrombomodulin expression of human vascular endothelium in vitro
57. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture
58. Regulation of thrombomodulin by tumor necrosis factor-alpha: Comparison of transcriptional and posttranslational mechanisms
59. Modulation of human endothelial thrombomodulin by neutrophils and their release products
60. Thrombomodulin: An overview and potential implications in vascular disorders
61. Increased circulating thrombomodulin in children with septic shock
62. Relationships between plasma levels of type II phospholipase A2, PAF-acetylhydrolase, leukotriene B4, complements, endothelin-1, and thrombomodulin in patients with sepsis
63. Soluble thrombomodulin increases in patients with disseminated intravascular coagulation and in those with multiple organ dysfunction syndrome after trauma: Role of neutrophil elastase
64. Cytokines, soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome
65. Endothelial cell and hemostatic activation in relation to cytokines in patients with sepsis
66. Increased plasma levels of soluble thrombomodulin in patients with sepsis and organ failure
67. Expression of tissue factor, thrombomodulin and E-selectin in baboons with lethal E. coli sepsis
68. Lack of suppressed renal thrombomodulin expression in a septic rat model with glomerular thrombotic microangiopathy
69. Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo
70. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: Lack of correlation with thrombomodulin suggests involvement of different pathological processes
71. Molecular mechanisms of thrombosis in meningococcal septicaemia: The role of the protein C pathway in vivo
72. Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon
73. Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits
74. Effects of a combined antithrombin III and protein C supplementation in porcine acute endotoxic shock